DrugDashboards

Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide

Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide · BROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL · Solution · Oral · PAI Holdings, LLC dba PAI Pharma

NDC 00121-0933-04 · 118 mL in 1 BOTTLE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $0.0804 per mL over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.05$0.1$0.15Jun 2022Sep 2026$0.0804
52 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$9.95
Reported to Texas DSHS · 2026 annual filing · PAI Holdings LLC dba Pharmaceutical Associates, Inc. / PAI Pharma

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$291,914
18,475 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA202940
TE code
AA
Approval date
Jul 21, 2014
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide (Solution)

LabelerStrengthFirst seenLast seen
PAI Holdings, LLC dba PAI PharmaBROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mLAug 26, 2026Sep 2, 2026
PAI Holdings, LLC dba PAI PharmaBROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 10 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 30 mg/5mLJul 22, 2026Aug 19, 2026
PAI Holdings, LLC dba PAI PharmaBROMPHENIRAMINE MALEATE 2 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mLJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide — NDC 00121-0933-04," retrieved September 3, 2026, https://drugdashboards.com/drug/00121093304.

Free to cite with attribution — see how the data is put together.